Generating CNS organoids from human induced pluripotent stem cells for modeling neurological disorders.
- Authors
- Brawner, Andrew T; Xu, Ranjie; Liu, Dingfeng; Jiang, Peng
- Year
- 2017
- Journal
- International journal of physiology, pathophysiology and pharmacology
- PMID
- 28694921
- PMCID
- PMC5498882
Understanding human brain development and disease is largely hampered by the relative inaccessibility of human brain tissues. Recent advances in human induced pluripotent stem cells (hiPSCs) have led to the generation of unlimited human neural cells and thereby facilitate the investigation of human brain development and pathology. Compared with traditional 2-dimensional (2D) culture methods, culturing the hiPSC-derived neural cells in a three-dimensional (3D) free-floating manner generates human central nervous system (CNS) organoids. These 3D CNS organoids possess the unique advantage of recapitulating multi-regional or region-specific cytoarchitecture seen in the early human fetal brain development. The CNS organoids are becoming a strong complement to the animal model in studying brain development and pathology, and developing new therapies to treat neurodevelopmental diseases. Further improvements to the long-term maintenance and neural maturation of the organoids may allow them to model neurodegenerative diseases. In this review, we will summarize the current development of hiPSCs to generate CNS organoids for modeling neurological disorders and future perspective.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | 2019 | 30087005 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Comprehensive Review on Utilizing Human Brain Organoids to Study Neuroinflammation in Neurological Disorders. | Rubio AD et al. | β | 2025 | β |
| Chimeric brain models: Unlocking insights into human neural development, aging, diseases, and cell therapies. | Papetti AV et al. | β | 2025 | β |
| Neural organoids as advanced tools for neurotoxicity modeling. | Majumder J et al. | β | 2025 | β |
| Rapid developmental changes in retinal organoids after brief exposure to extrinsic electrical fields | Thomas B et al. | β | 2024 | β |
| Advances in current <i>in vitro</i> models on neurodegenerative diseases. | Pereira I et al. | β | 2023 | β |
| Fountain of youth-Targeting autophagy in aging. | Danics L et al. | β | 2023 | β |
| Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems. | Silva-Pedrosa R et al. | β | 2023 | β |
| Toward the next generation of vascularized human neural organoids. | Li M et al. | β | 2023 | β |
| Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease. | Brockhausen I et al. | β | 2022 | β |
| MECP2-related pathways are dysregulated in a cortical organoid model of myotonic dystrophy. | Morelli KH et al. | β | 2022 | β |
| Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities. | Chien Y et al. | β | 2022 | β |
| Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research. | Van Breedam E et al. | β | 2022 | β |
| Advances in neural organoid systems and their application in neurotoxicity testing of environmental chemicals. | Zheng Y et al. | β | 2021 | β |
| Brain organoids: A promising model to assess oxidative stress-induced central nervous system damage. | Oyefeso FA et al. | β | 2021 | β |
| Comparison of Acute Effects of Neurotoxic Compounds on Network Activity in Human and Rodent Neural Cultures. | Saavedra L et al. | β | 2021 | β |
| Non-canonical Targets of HIF1a Impair Oligodendrocyte Progenitor Cell Function. | Allan KC et al. | β | 2021 | β |
| Retinal Organoids: Cultivation, Differentiation, and Transplantation. | Li X et al. | β | 2021 | β |
| The Application of Brain Organoid Technology in Stroke Research: Challenges and Prospects. | Song G et al. | β | 2021 | β |
| Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. | Silva MC et al. | β | 2020 | β |
| Neural tissue engineering with structured hydrogels in CNS models and therapies. | George J et al. | β | 2020 | β |
| Glucocerebrosidase and its relevance to Parkinson disease. | Do J et al. | β | 2019 | β |
| Measles Encephalitis: Towards New Therapeutics. | Ferren M et al. | β | 2019 | β |
| OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome. | Xu R et al. | β | 2019 | β |
| Organs to Cells and Cells to Organoids: The Evolution of <i>in vitro</i> Central Nervous System Modelling. | Pacitti D et al. | β | 2019 | β |
| Pluripotent Stem Cell-Derived Cerebral Organoids Reveal Human Oligodendrogenesis with Dorsal and Ventral Origins. | Kim H et al. | β | 2019 | β |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | β | 2019 | β |
| 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. | Centeno EGZ et al. | β | 2018 | β |
| Intestinal organoids for modelling intestinal development and disease. | Fair KL et al. | β | 2018 | β |
| Small-molecule induction of AΞ²-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes. | Pavoni S et al. | β | 2018 | β |